Nano-X Imaging Ltd. (NASDAQ: NNOX) has entered into a securities purchase agreement with a single long-term institutional investor for a registered direct offering expected to generate approximately $8 million in gross proceeds before fees and expenses. The financing involves the sale of 8 million ordinary shares, or prefunded warrants in lieu thereof, along with warrants to purchase up to an additional 8 million ordinary shares. The combined purchase price is $1.00 per share and accompanying warrant, with the warrants carrying a $1.15 exercise price, becoming exercisable six months after issuance and expiring five years after closing.
The offering is anticipated to close on or about Aug. 7, 2026, subject to customary closing conditions. Nano-X stated it intends to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction. The full press release is available at https://ibn.fm/5fNi8.
This capital raise comes at a critical time as Nano-X continues to build out its comprehensive medical imaging and healthcare services platform. The company is focused on driving the world's transition to preventive healthcare by delivering an integrated, end-to-end solution that combines affordable imaging hardware, advanced AI-based algorithms, cloud-based software, remote radiology access, health IT solutions, and a marketplace. By integrating these components, Nano-X aims to enable earlier detection of disease, improve clinical efficiency, and broaden access to care both within and beyond traditional hospital settings.
The Nanox ecosystem includes several key products and services. The Nanox.ARC is a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability. Nanox.AI offers a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease. Nanox.CLOUD provides a cloud-based platform for secure data management, storage, and advanced imaging analytics. Additionally, Nanox.MARKETPLACE and USARAD Holdings offer access to remote radiology and cardiology experts, while Nanox Health IT delivers RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
The implications of this offering are significant for Nano-X's growth strategy. The funds will support the company's ongoing efforts to lower barriers to adoption, improve utilization, and advance preventive care worldwide. By strengthening its balance sheet, Nano-X can continue to invest in its proprietary digital X-ray technology and AI-driven analytics, which are central to its vision of expanding the reach of medical imaging. The participation of a long-term institutional investor signals confidence in the company's long-term prospects and its ability to execute on its strategic objectives.
As the healthcare industry increasingly shifts toward preventive and early detection models, Nano-X's integrated platform positions it well to capitalize on this trend. The additional capital will enable the company to enhance its product offerings, expand its market presence, and potentially accelerate the commercialization of its technologies. For investors, this offering provides an opportunity to support a company that is at the forefront of transforming medical imaging and improving patient outcomes through innovative technology.
